Patent Application
20230193331
This invention relates to a standardized plant extract, in particular, extract from biomass of in vitro cultures, where the plant extract contains valuable bioactive compounds (BAC) and secondary metabolites, and can be used for the preparation of agents for the pharmaceutical, cosmetics or food industries, as well as to the method of preparation of such extract.
Plants in nature contain a huge variety of BAS, and their origin, growth conditions, harvesf time, extraction technology, etc., affect the quality of the product.
Cultivated medicinal plants have many advantages over wild plants. Their growth can be monitored and they can be harvested at the most favourable time, while the proximity to unsuitable plant species can be avoided.
Haberlea is a monotypic genus, H. rhodopensis Friv. (Rhodopean Silivryak), or (HR) for short, being its only member. The plant is a relic of the Tertiary period, endemic to Central and Southern Bulgaria, found in the Balkan and the Rhodope Mountains, and in Northeastern Greece - the Rhodope Mountains, Mount Pangaion and Falakro Mountain. For centuries, H. rhodopensis has been traditionally used in ethnopharmacy and local traditional medicine (1).
It is known that plant extracts have been isolated from HR leaves. The biocompounds isolated from plant extracts are a source of essential natural ingredients. Apart from fruits and vegetables, polyphenols, glycosides, sugars, etc. are also found in plants, and, due to their physiological functions, play a significant role in human health. An ethanol extract of HR is known to have been obtained by spray drying of the whole plant, followed by three-hour ethanol extraction under agitation at room temperature, filtration, separation of the insoluble matter, followed by vacuum concentration and freeze drying to obtain the extract. The same source also provides information of an aqueous HR extract, where the whole plant is spray dried, extracted with 120° C. hot water for 20 minutes in an autoclave, followed by separation of the insoluble matter through filtration at high temperature, and freeze drying. The extracts obtained have anti-aging, antioxidant, skin-lightening and immunostimulatory effeds (5).
There is a report on extract of HR obtained by hydroalcoholic extraction (ethanol/water, unspecified method of preparation) and purified by gel-filtration chromatography on a Sephadex LH-20, containing an isolated fraction particularly rich in phenylethanoid glycoside - a myconoside responsible for the bioactivity of Haberlea extracts. In the same source, the effectiveness of the extract was observed and myconoside was reported to stimulate the antioxidative protection of the skin, to improve its elasticity by stimulating the synthesis of extracellular structures, and to possess cytoprotective and UV-protective effects, serve as a skin anti-aging agent protecting it against oxidation, increasing its elasticity, enhancing its rediance and to have potential cosmetic applications (3).
It is also known that the phytochemical composition of 70% ethanol extract of HR leaves contains a large group of major bioactive compounds, including secondary metabolites, such as: phenolic acids, flavonoids, fatty acids, phytosterols, carotenoids, soluble lipids, oligo-and polysaccharides, free sugars, polyols, organic acids, including myconoside, with proven antioxidant and hepatoprotective effects (1).
Data on the phytochemical profile of methanol extract of HR leaves prepared by using a combination of liquid/liquid extraction, preparative and semi-preparative HPLC containing two phenolic glycosides: myconoside and paucifloside is also available. The myconoside-rich fraction (caffeoyl phenylethanoid glycoside) has a potential role in plant survival, and possesses antioxidant activity due to the presence of caffeoyl and two free hydroxyl groups in its phenyl ring. The major BAC groups and secondary metabolites found in various HR extracts during normal growth and during the dry period of plant development are organic acids, fatty acids, amino acids, phenolic acids, ahd sugars (4). Nowadays, HR extracts obtained directly from the naturally growing species have been successfully applied in cosmetics, homeopathy and pharmacy, owing to their proven antimicrobial, antiviral, antioxidant, immunomodulatory, cytotoxic, anti-cancer, chemopreventive, gene-protective, and radioprotective properties.
On the other hand, being particularly valuable and rare endemic species, HR is among the plant species whose collection from nature is prohibited. In recent years, for instance, in vitro systems for the regeneration and micro-propagation of HR have been established with the aim to protect the natural populations of this rare plant species. An in vitro bank of HR plants from different locations has been set up. The same source also describes an effective method of regeneration and micro-propagation in which the seeds of the plant species are sterilized with 70% EtOH for 1 min, treated with hypochloride for 6-10 min, and with 0.1% HgCh for 3-5 min, and triple-rinsed with distilled water, and the resulting sterile HR seeds are placed on classic hormone-free MS medium (as well as MS B5, WPM), to germinate for 3-4 months and obtain seedlings. Subculturing of the plant clusters for 1-1.5 months gave in vitro systems of fully developed plants, ready for transformation in the course of 6-7 months under non-sterile conditions jn a controlled greenhouse environment (2).
At the same time, plant biotechnology, in particular in vitro cultivation of plant cells, has become a promising tool for sustainable and continuous production of BAC from plants. The principles of plant cell culture and plant cell propagation in solid and liquid nutrient media, as well as the general processes associated with the establishment and cultivation of plant cells, have been described for other plant species, different from HR.
Separate extracts from plant cell cultures of Rosa sp. have been obtained, containing valuable natural products (NP) for cosmetic skin and hair care, preventing signs of aging, according to (6). Plant cell biomass is used for the production of phenylpropanoids from Ajuga repens, and verbascoside from Olea europea, Syringa vulgaris or Appia citobara, as well as production of verbascoside-standardized extract from Syringa vulgaris cell cultures, with proven antioxidant activity, effective in treating acne and preventing hair loss, according to (7).
A preparation in the form of in vitro culture extract of Argania spinosa, intended for the treatment of skin aging and skin inflammation has also been made, according to (8). Standardized extract, obtained from in vitro undifferentiated plant cells of Dracocephalum ruyschiana, containing BAC with proven antiradical activity and cosmetic application for skin protection and regeneration, where in vitro propagated undifferentiated cells of Dracocephalum ruyschiana, grown in semi-solid or liquid medium have been obtained in darkness or under photoperiod for 14-16 hours with separation of the cellular biomass followed by biomass extraction with ethanol or ethanol, glycerol and water in ratios of 20:20:60 to 50:50:0 (v/v), drying of the biomass and further extraction with the same extractant, according to (9).
So far, there has been no report on extract from biomass of HR in vitro cultures, with BAG and secondary metabolites.
In spite of the fact that, the general principles for the cultivation of plant cells are not applicable to large-scale cell propagation for production purposes, and specific technological processes need to be developed. In order to maintain plant in vitro cultures (differentiated or non-differentiated) under in vitro cultivation conditions, it is important to determine the optimal, strictly specific ratio of growth regulators (auxins, cytokinins and gibberellins), and establish it for each cell line (each plant species). Changes in cell culture conditions, as well as the use of elicitors, precursors and absorption matrices, are crucial for the production of specific bioactive compounds/metabolites, and are specific to the plant species used and to the desired target compounds.
However, the synthesis of valuable BAC and metabolic constituents in in vitro cultures is a complex process with many unknown parameters. The accumulation of natural ingredients and secondary metabolites in the cellular biomass results from the dynamic balance between biosynthesis, biotransformation and biodegradation. It is important to select the appropriate and optimal conditions - nutrient medium and stimulating factors for each ingredient inherent to the intact plant.
Often, the natural products obtained from traditional extracts are of insufficient homogeneity, and the amounts of the target therapeutic ingredients tend to vary seasonally and geographically when compared to those obtained from in vitro cultures. It is also essential to work with standardized raw materials for the purposes of obtaining in vitro biomass extract and its incorporation into products for the cosmetic, pharmaceutical or food industries.
The problem of this invention is to obtain a standardized extract, in particular extract from HR in vitro cultures (seedlings, shoot cultures, root cultures (normal, adventitious and hairy roots), somatic embryos, callus cultures, cell suspension cultures) with a guaranteed content of the phenylethanoid glycoside - myconoside, with invariable physico-chemical characteristics and composition of the concomitant BAG/components, obtained by biotechnological method with a maximally efficient design.
The problem according to the present invention is solved by a standardized plant extract, in particular extract from biomass of in vitro cultures (seedlings, shoot cultures, root cultures (normal, adventitious and hairy roots), somatic embryos, callus cultures, cell suspension cultures) of HR, containing BAC, including their secondary and primary plant metabolites - fatty acids, sterols, organic acids, amino acids, free phenolic acids, and sugars. The amount of BAC in the extract in wt. % is: fatty acids from 0.5 to 1.5, sterols 0.5 to 1.0, organic acids 4.0 to 6.0, amino acids 8.0 to 12.0, free phenols 3.0 to 6.0, sugars 45.0 to 55.0, and polyphenolic compounds 25.0 to 35.0%, containing phenylethanoid glycoside - myconoside accounting for between 70 and 96% of the polyphenolic fraction. The resulting extract from biomass of HR in vitro cultures is rich and standardized in myconoside, the amount of which ranges from 18% to 35% of the total extract. The dissolution of the standardized extract in glycerol yields a product with a controlled content of myconoside from 0.01 to 15.00% in its composition, according to the needs of the relevant industry - pharmaceutical, food or cosmetic.
The described standardized extract from in vitro cultures according to the present invention is prepared by a method comprising the following essential steps:
Suitable nutrient media are standard semi-solid and liquid variants selected from among: MS (Murashige and Skoog), WP (McCown Woody Plant), LS (Linsmaier and Skoog), Gamborg B5, Heller, Nitsch, Schenk and White, or with modified macrosalts composition, micro-salts and vitamins. For the needs of this method, the media were further modified by adding a carbon source, such as sucrose and/or glucose (1% to 9%), activated charcoal 0-5%, reducing agent, such as 2-Mercaptoethanol and/or Dithiothreitol, in concentrations from 0 to 10 mg/l, antioxidants, such as ascorbic acid and/or citric acid from 0 to 10 mg/l, gelling agent agar-agar or gellrite at concentrations of 0.1% to 10%.
The main growth regulators are selected from among: auxins (picloram and a-naphtalene acetic acid), cytokinins (kinetin and 6-benzylaminopurine), and/or gibberellins at concentrations of 0-20 mg/l. Picloram and/or a-naphthalene acetic acid may be used as auxins, such as cytokinins - kinetin and/or 6-benzylaminopurine, with Gibberellic acid 4 + 7 and/or Gibberellic acid A3. Other possible auxins are: lndole-3-acetic acid, lndole-3-butyric acid, Dicamba, p-Chlorophenoxyacetic acid and B-Naphtoxyacetic acid), cytokinins: 2-iP, 4-CPPU, 6-benzylaminopurine riboside, Dihydrozeatin, Zeatin, Meta-tropoline and Thidiazuron) and gibberillins: Gibberellic acid.
The elicitors used are selected from among: biotic, such as polysaccharides or chitosan; or abiotic, such as methyl jasmonate, jasmonic acid, abscisic acid or with a physical factor (osmotic agents, UV light), which, when added at extremely low concentrations, serve as signals to stimulate secondary metabolism of the plant cell. Other strategies, such as feeding with fresh nutrient media, or adding precursors (amino acids and sugars), or introducing a second phase (activated charcoal or absorbent resin) into the cultivation system to capture secreted secondary metabolites, may also be applied.
Cultivation of HR differentiated and undifferentiated in vitro cultures is carried out as follows:
The resulting extract produced by in vitro HR cultures biomass contains the target bioactive compounds, is rich in polyphenolic compounds of up to 35% (consisting of 70- 96% myconoside), sugars of up to 55% of the mixture, as well as amino acids of up to 12%, making the extract extremely valuable.
The standardized content of the phenylethanoid glycoside - myconoside, makes the extract particularly valuable because of its protective effect on human health, its successful use due to its pharmaceutical and cosmetic effects, as well as in functional nutrition. The antioxidant effect of myconoside makes it appropriate for use in cosmetics due to its anti-aging, anti-wrinkle, and anti-pigmentation action.
The method developed for preparing the extract according to this invention, with optimally selected steps, specific conditions, parameters, such as temperature, time, stirring, light, growth factors, etc., obtains not only maximum volumetric productivity of the target substances and myconoside, but also stable productivity of the plant in vitro cultures, and is a reliable efficient 24/7 continuous system for production of NPs.
Dependence on natural factors, limited availability and protection of HR rare wild plant populations are eliminated. The limitations posed by seasonality and slow HR growth are also avoided by developing a renewable, environmentally-friendly method. The method provides alternative, renewable and sustainable sources of raw material necessary to obtain the target extract.
Batch homogeneity of the final NP is ensured, as well as stable quality and guaranteed amount of myconoside in the standardized extract produced by HR in vitro cultures.
In addition, the appropriate cultivation media used, together with the optimum levels of growth factors and stimulating agents added, lead to the successful formation of in vitro cultures (seedlings, shoot cultures, root cultures, somatic embryos, callus cultures, cell suspension cultures) and generation of biomass containing the target valuable BAC. The resulting cultures have a significant scale-up potential in industrially relevant bioreactors and temporary immersion systems designed to maximize the yield and content of biosynthetic NPs.
The type and concentration of stimulating agents used (elicitors, precursors and absorption phases), the age and stage in the in vitro culture development at the time of extraction are especially important factors that are optimized and contribute to higher levels of biosynthesis and accumulation of NPs with a particularly complex molecular structure with the method used.
The risk of microbial contamination is eliminated as well as the contamination with biological material of other plant, fungal, microbial or animal species of the in vitro biomass and extract produced. Consequently, the extract having a naturally-occurring chemical composition and content of various and valuable BACs, as well as the method used to obtain maximum biomass yield and extract are considered to be preferable and especially suitable for standardization in the phenylethanoid glycoside, for implementation in the food, cosmetic or pharmaceutical industries.
Hereinafter, the present invention is described in more detailed examples, which however are not intended to limit the present invention:
Ten to 50 pieces of 0.6 mm x 0.1 mm seeds of HR are washed twice, for 30 60 min in sterile distilled water with added gibberellins 0.5 mg/I, treated with 70% ethanol for 100 sec and with 8% calcium hypochlorite for 50 min, followed by washing twice with sterile distilled water for 5-10 min, and drying the resulting sterile seeds on sterile filter paper for 10-15 min.
The sterile seeds are evaluated for quality and morphology, dead and morphologically altered individuals are removed, and transferred for initiation on semi-solid, pre-sterilized at 121° C. for 30 min standard MS nutrient medium with 5% sucrose and 5% agar, pH 6.0. Cultured in a thermostat at 28° C. ± 2° C. in darkness, for 2 weeks, with asepsis monitored until 95 to 100% of seedlings appear.
The seedling in vitro cultures obtained are transferred for independent growth on semi-solid MS nutrient media with added 5% sucrose and 5% agar-agar, at pH 6.0. Cultivation is in a thermostat at 28 ± 2° C. in light/dark mode for 12 hours for 30-35 days until morphologically stable lines are obtained. Myconoside overproduction lines are selected by periodic monitoring the amount of myconozide produced in the cultures and selecting 25% of the high-yielding lines from the total number of generated in vitro lines.
The selected lines are maintained by periodic subculturing at every 30 days on fresh semi-solid nutrient medium, the same as in step 1.3, changes in morphology and stability being monitored, and the amount of myconoside analysed. 10 g of biomass are taken from the high-yielding lines and cultivated in sterile liquid MS medium with the same additives and pH in a 2000ml flask on an orbital shaker at 140 rpm, with changes in morphology, growth, homogeneity, stability and amount of myconoside being monitored, and the 95-100% of the most adaptive lines continue for subsequent submerged cultivation as inoculum.
Inoculation is with 25 g of fresh weight/l of liquid culture, at 20 days of age (exponential phase of growth). Cultivation is performed at 28° C. in light/dark for 12 hours for 5 weeks in a temporary immersion system with an immersion period of 25 min and exposure period of 6 hours. As a result, 180 g of fresh biomass per litre is obtained, and the myconoside content is 105 mg/g dry biomass;
To 20- to 40-day-old biomass (at exponential phase of growth), abiotic elicitors jasmonic acid and methyl jasmonate are aseptically added at a concentration of 5 mg/l, and cultivated under the above conditions for 12 days. At the end of the process, enriched biomass with a myconoside content of 152 mg/g dry biomass is obtained. Separation of the biomass from the culture liquid by filtration through a sterile sieve is followed by washing with sterile distilled water and drying in a ventilation oven at 60° C. The yield is 15 g dry biomass per litre. The quality of the resulting biomass in each batch is monitored for myconoside content and phenolic compounds.
The culture fluid is collected and dried in a vacuum evaporator at 60° C. The yield is 30 g/1 dry weight.
Comparative HPLC profiles for myconoside content of biomass from HR in vitro cultures (A), wild plant biomass (B), and extract from biomass from HR in vitro seedling cultures (C) are presented in Fig. 1.
The resulting dry biomass and culture liquid are mixed and homogenized in a homogenizer. For this purpose, 2 kg of dry biomass and 2.5 kg of dry culture liquid (obtained from 200l in vitro seedling culture grown under submerged conditions) are used.
A water-ethanol mixture of 70% ethanol is added at hydromodule 20 (weight to volume) for 35 hours, at 40° C. with sonication for 15 min every 4 hours, the resulting precipitate is removed by vacuum filtration and the filtrate is collected and dried by vacuum evaporation at 40° C. to obtain a viscous concentrate containing 12% moisture.
One kg of biomass extract from in vitro seedling cultures of HR, containing 208 g/kg myconoside is obtained.
The extract is characterized phytochemically, the results are presented in Table 1. The amount of myconoside and the contents of phenolic compounds, fatty acids, organic acids, amino acids, sugars and sterols are monitored by HPLC and GC/MS methods.
HPLC content of myconoside in the extract from HR in vitro biomass obtained according to Example 1 and compared with standard 70% ethanol extract from HR plants growing in their natural habitat, as well as standard 70% ethanol extract from in vitro seedling culture of HR are presented in Table 2.
To 240.4 g of the extract, containing 208 g/kg myconoside, 759.6 g of glycerol is added to produce 1 kg of extract, containing 5% myconoside. The resulting mixture is stirred until complete homogenization of the extract using a vibrating stirrer. The resulting solution is packaged in sterile packs and stored for use in cosmetic products, pharmaceuticals or food supplements. For cosmetic purposes, the standardized extract from HR in vitro cultures is suitable in amounts from of 0.1 to 15% for products like creams, emulsions, gels, etc. Table 3 also presents a comparative analysis of the antioxidant properties of the extract from HR in vitro cultures, obtained according to Example 1, compared to the standard 70% ethanol extract from HR plants growing wild. The ability of the extract to capture free DPPH and ABTS radicals, as well as the ability to reduce copper (II) and iron (III) ions, was evaluated.
Agilent Technology Hewlett Packard 7890 A +/MSD 5975 apparatus (Hewlett Packard, Palo Alto, CA, US) coupled with an Agilent Technology 5975C inert XL El/Cl MSD Mass Spectrometer (Hewlett Packard, Palo Alto, CA, US). HP-5MS column (30 m x 250 µm x 0.25 µm) at 60° C. temperature program for 2 min, with a temperature rise to 260° C. with 5° C. per minute, and exposure at 260° C. for 8 min. The volume of the injected sample is 1 µl at a split ratio of 10:1. Injector temperature 250° C. with a flow carrying gas (helium) of 1 mL/min. The El/MS spectrum is recorded at 70 eV.
HPLC system, Waters 1525 Binary pump (Waters, Milford, MA, USA), Waters 2487 Dual A Absorbance Detector (Waters, Milford, MA, USA) operated by Breeze 3.30 software; Supelco Discovery HS C18 column (5 µm, 25 cm x 4.6 mm), t 28° C.; mobile phase with a gradient of 2% acetic acid and acetonitrile;
The method is the same as in Example 1, except that leaves of HR are processed instead of seeds, and root cultures are prepared and used as in vitro culture. Cultivation is carried out in a bubble column, biosynthesis is enhanced by feeding instead of elicitation, and the resulting extract contains only accumulated biomass without culture liquid.
Three to ten 2-5 cm young HR leaves are washed for 3 min in sterile distilled water with added detergent (Tween 80), treated with 80% ethanol for 60 sec and with 6% calcium hypochlorite for 30 min, triple-washed with sterile distilled water for 3 min and dried on sterile filter paper for 2 min.
The sterile leaves are processed by excising dead areas. The leaves are then cut into 0.5 to 1.0 cm segments and initiated on semi-solid, pre-sterilized at 121° C. for 30 min standard B5 nutrient medium supplemented with 4% sucrose and 8 mg/l picloram, gellrite 3%, and additional supplementation of 5 mg/l ascorbic acid and 5 mg/l 2-Mercaptoethanol, pH 5.5, cultured at 24° C. ± 2° C. in darkness for 4 weeks, with monitoring for asepsis until root cultures are formed from the leaves in 90% of the explants.
The resultant in vitro cultures of adventitious roots are cultured individually on the same medium as in Example 2, step 1.2, with the addition of 3 g/l activated charcoal, in a thermostat at 24° C. in darkness for 37 days to obtain morphologically stable myconoside overproducing lines, where 15% of high-yielding lines are selected from the total number of in vitro lines generated.
The selected root culture lines are maintained by periodic subcultivation every 37 days on the semi-solid fresh medium in step 1.3 of Example 2, changes in morphology and stability are monitored, and the amount of myconoside is determined. 15 g of biomass from the high-yielding lines are cultivated in sterile liquid B5 medium with the same additions as in step 1.3 of Example 2 in a 500 ml flask on an orbital shaker at 100 rpm, and 85% of the most adaptive lines continue for the subsequent submerged cultivation as inoculum.
30 g fresh weight/l of 30-day-old root culture at the exponential phase of growth are cultured on liquid B5 medium with the same additions as in step 1.3, at 24° C. ± 2 in darkness for 4 weeks in a bubble column at air flow rate of 0.3 l/l/min. 130 g/l of fresh biomass yield dry biomass with a myconoside content of 120 mg/g.
The biomass, which is at the late exponential phase of growth (35 days old), is aseptically supplemented with fresh liquid B5 medium up to the maximum working volume of the bioreactor and cultivated under the conditions described above for a period of 10 to 15 days. The result at the end of the process is enriched biomass containing myconoside of 170 mg/g dry biomass. The resulting biomass is separated from the culture fluid by filtration, washed and dried. The yield is 12 g of dry biomass per litre.
3 kg of dried biomass from the in vitro cultivated root culture is ground and subjected to extraction by maceration with 80% aqueous ethanol mixture at hydromodule 40 (weight to volume) for the same period of time and at the same temperature as in Example 1, except that it is conducted without sonication to obtain viscous concentrate containing 15% moisture. 500 g of biomass extract from in vitro HR root culture containing 280 mg/g myconoside are obtained.
357.1 g of the myconoside-rich in vitro root culture of HR are weighed in a vessel. 642.9 g of glycerol are added to the desired weight of 1 kg of extract containing 10% myconoside. The resulting mixture is stirred until complete homogenization of the extract with sonication, packaged in sterile packs and stored for future use.
Conducted like Example 1, except that instead of seeds, ovaries are processed, and instead of seedling cultures, callus and cell suspension cultures are obtained and used as in vitro cultures. Cultivation is carried out in Erlenmeyer flasks.
Two to five 5 newly-formed 0.2-0.5 cm HR ovaries are washed for 1-2 minutes in sterile distilled water, treated with 70% ethanol for 90 seconds, and 10% sodium hypochlorite for 40 minutes, followed by washing with sterile distilled water for 1 min and dried on sterile filter paper for 1 min.
The resulting sterile ovaries are cut horizontally in half and transferred for initiation on semi-solid, pre-sterilized at 121° C. for 30 min standard WP nutrient medium supplemented with 2% sucrose, 1 mg/l 1-naphtalene acetic acid, 1 mg/l 6- benzylaminopurine and agar-agar 4%, pH 5, and cultured at 26° C. ± 2° C. in darkness for 3 weeks, with monitoring for asepsis until callus formation in 93% of explants.
The resulting in vitro callus cultures are ready for independent growth in a thermostat on the same medium as in step 1.2 with added citric acid of 3 mg/l and 1 g/l activated charcoal at the same temperature, in darkness for 27 days to obtain morphologically stable myconoside overproducing lines, where 11% of high-yielding lines are selected from the total number of generated in vitro lines.
The selected callus culture lines are maintained by periodic subcultivation every 27 days on fresh semi-solid WP nutrient medium as in the previous step, changes in morphology and stability are monitored, and the amount of myconoside is analyzed. The same amount as in Example 2 step.2.2 of biomass from high-yielding lines is cultured in sterile liquid WP medium with the same additions as in the previous step in a 1000 ml flask on an orbital shaker at 80 rpm to obtain a cell suspension culture consisting of small and medium-sized aggregates, the 75% most adaptable of the lines continue for the next submerged cultivation as inoculum.
100 g of fresh weight/t 7-day-old cell suspension culture at the exponential phase of growth are cultured at 26° C. in darkness for 9 days in 2000 ml flasks on an orbital shaker at 80 rpm. 110 g/l fresh biomass with myconoside content in the resulting biomass of 80 mg/g dry biomass is obtained.
The biomass at the late exponential growth phase (6 days old) is aseptically supplemented with 1 g of sterilized absorption resin (Amberlite XAD7) as a second phase. Cultivation continues for a further 4 days to obtain enriched biomass with myconoside content of 100 mg/g dry biomass. It is further treated as in Example 1, and the biomass and culture fluid are freeze dried at -40° C. The yield is 9 g dry biomass per litre and 15 g dry weight culture fluid per litre.
The total of 1 kg of dried biomass and culture fluid are homogenized and extracted by maceration with a 30% ethanol water-ethanol mixture at hydromodule 10 (weight to volume) at the same temperature and for the same duration, with precipitation, separation and drying as in Example 1 to obtain a viscous concentrate containing 20% moisture. 100 g of extract from biomass of Haberlea rhodopensis in vitro cell suspension culture containing 150 mg/g myconoside are obtained.
100.0 g of the myconoside-rich HR extract obtained from in vitro cell suspension culture are weighed. 400.0 g of glycerol are added thereto to the desired weight of 500 g of extract containing 3% myconoside. The mixture is stirred until the extract is completely homogenized using a rotary or high-pressure homogenizer, and the resulting solution is packed in sterile containers and stored for future use.
DPPH (2,2-diphenyl-1-picrylhydrazyl) / HR extract / 0.1 mM solution of DPPH radical / in darkness, at 21° C. for 15 minutes /% decrease in absorption at λ = 517 nm compared to the control sample (with methanol addition)/ determination of EC50 (effective concentration inhibiting 50% of DPPHradial in 0.lmM DPPH solution).
TEAC / ABTS (2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) radical/HR extract is added to a solution of pre-generated ABTS radical/ darkness at 21° C. for 15 minutes/ % decrease in absorption at λ = 734 nm compared to that of a control (with methanol addition)/ result as mM Trolox ((±) -6-hydroxy-2,5, 7,8-tetramethylchroman-2-carboxylic acid).
The following are used to evaluate the reducing capacity:
Figure 1. HPLC profiles for myconoside content in in vitro biomass of Haberlea rhodopensis (A), wild plant biomass (8), and extract from in vitro seedling culture biomass of Haberlea rhodopensis (C).
| Number | Date | Country | Kind |
|---|---|---|---|
| 113104 | Mar 2020 | BG | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/BG2020/000016 | 3/19/2020 | WO |
